iRhythm Technologies, Inc. Loss Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Submit Transaction Detail Now (Optional)

- OR -

    This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

    FAX: 212-363-7171

    On March 13, 2019, Kerrisdale Capital issued a report alleging that “at the core of iRhythm’s revenue base is an exceedingly generous, but increasingly fragile, reimbursement regime.” Then on March 27, 2019, Washington Analysis LLC issued a report estimating that the Company could face a 45%-65% reimbursement cut for its Zio XT Patch. Following this news, shares of iRhythm fell from a close of $87.34 on march 13, 2019, to close at $74.96 on March 29, 2019.

    On November 13, 2019, iRhythm disclosed its inability to file its quarterly report in a timely manner, citing accounting errors affecting prior periods that may result in correction of previously issued annual and quarterly financial statements. On this news, iRhythm’s stock price fell over 6%.